Tolero Pharmaceuticals
Salt Lake City
About Tolero Pharmaceuticals
Tolero Pharmaceuticals is a biopharmaceutical company that discovers and develops novel therapeutics to treat and cure cancer and other life-threatening diseases in the United States. Its products include TP-0413 that targets a signaling pathway complicated in the regulation of serum iron levels for individuals suffering from chronic inflammatory diseases, such as cancer and rheumatoid arthritis; TP-0829, which targets a vital component of the B-cell receptor signaling pathway for the treatment of B-cell lymphomas, B-cell leukemia, and multiple myeloma; and TP-0903, a dual-targeted agent that inhibits two signaling pathways for pancreatic cancer cell growth and survival, and for the maintenance of the tumor stromal cells. The company’s products also comprise TP-0227 that targets a signaling pathway deregulated in cancer cells particularly in endometrial carcinomas; and TP-1149 which targets a cellular mechanism to render myeloma cells resistant to current therapeutic approaches. Tolero Pharmaceuticals, Inc. has a strategic partnership with MannKind Corporation. The company was founded in 2011 and is based in Salt Lake City, Utah.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $25.9M
- Funding stage: M&A
- Last round: Series B (Nov 2014)
- Website: toleropharmaceuticals.com
- Phone: 801-285-6003
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/tolero-pharmaceuticals-3446233 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.